Skip to content

Emerging wellness, examined.

Tesamorelin

Also discussed as: Egrifta

A growth-hormone-releasing hormone analogue with an FDA-approved indication for excess abdominal fat in adults with HIV-associated lipodystrophy. That approval is not a general wellness or anti-aging approval.

Tesamorelin

Regulatory status
FDA approved for a specific HIV lipodystrophy indication
Human evidence
Approved labeling for one indication only
Preclinical evidence
Developing
Known risks
See evidence review
Major unknowns
Long-term safety
Standardized human dosing
Clinical effectiveness
Last evidence review
2026-09-24
Last regulatory review
2026-09-24

A growth-hormone-releasing hormone analogue with an FDA-approved indication for excess abdominal fat in adults with HIV-associated lipodystrophy. That approval is not a general wellness or anti-aging approval.

Why it is trending: public search and clinic marketing have moved faster than a settled human evidence base. This page does not score that attention as benefit or safety.

Human evidence

Human evidence is very limited for a consumer conclusion, except where an approved labeling exists for a specific indication. This review does not invent trial results.

Preclinical evidence

Animal and laboratory papers exist for several of these compounds. Preclinical work does not establish human effectiveness.

Risks and unknowns

Known risks include an incomplete human safety picture and, outside regulated manufacturing, uncertain product identity. Major unknowns include long-term safety, standardized human dosing, and clinical effectiveness.

Reviewed 24 September 2026. Regulatory status can change. Check the FDA record before treating any sentence here as current law.

Related reading

Sources

  1. FDA drugs database and consumer updates
  2. ClinicalTrials.gov
  3. PubMed

This page is journalism and research literacy. It is not medical advice and not a product recommendation.